electroCore Announces Fourth Quarter and Full Year 2020 Financial Results
March 11, 2021 16:05 ET
|
electroCore
Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019 Further reduced net cash usage to $3.7 million in the fourth quarter 2020 versus $4.1 million...
electroCore to Announce Fourth Quarter and Year Ended December 31, 2020 Financial Results on Thursday, March 11
March 04, 2021 08:30 ET
|
electroCore
ROCKAWAY, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth...
electroCore to Participate at Two Upcoming Investor Conferences
March 03, 2021 16:30 ET
|
electroCore
ROCKAWAY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in two...
electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia
February 28, 2021 16:00 ET
|
electroCore
ROCKAWAY, N.J., Feb. 28, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement...
electroCore Announces Two-Year Extension of gammaCore™ Listing in the NHS Supply Chain Catalogue
February 23, 2021 08:00 ET
|
electroCore
ROCKAWAY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore will continue to be listed in...
electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine
February 16, 2021 08:00 ET
|
electroCore
ROCKAWAY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that on Friday, February 12, 2021, the company...
electroCore Announces Completion of Enrollment in SAVIOR-1 Study of Non-Invasive Vagus Nerve Stimulation (nVNS) in COVID-19 Patients Exhibiting Respiratory Symptoms
February 11, 2021 08:00 ET
|
electroCore
ROCKAWAY, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the completion of patient enrollment in...
electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Reduce Ileus After Major Colorectal Surgery
February 09, 2021 08:00 ET
|
electroCore
ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper,...
electroCore to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 03, 2021 08:00 ET
|
electroCore
ROCKAWAY, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside...
electroCore Announces Full Enrollment of TR-VENUS study of Non-Invasive Vagal Nerve Stimulation (nVNS) for the Acute Treatment of Stroke
February 02, 2021 08:00 ET
|
electroCore
ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the...